drugset / Trial / NCT00592475
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conivaptan | Small molecule | 2.5 mg | Intravenous |
| Subject | Conivaptan | Small molecule | 5 mg | Intravenous |